Cargando…

High-volume infiltration analgesia in bilateral hip arthroplasty: A randomized, double-blind placebo-controlled trial

BACKGROUND AND PURPOSE: High-volume infiltration analgesia may be effective in postoperative pain management after hip arthroplasty but methodological problems prevent exact interpretation of previous studies. METHODS: In a randomized, double-blind placebo-controlled trial in 12 patients undergoing...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen, Lasse Ø, Otte, Kristian S, Husted, Henrik, Gaarn-Larsen, Lissi, Kristensen, Billy, Kehlet, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237031/
https://www.ncbi.nlm.nih.gov/pubmed/21751861
http://dx.doi.org/10.3109/17453674.2011.596063
Descripción
Sumario:BACKGROUND AND PURPOSE: High-volume infiltration analgesia may be effective in postoperative pain management after hip arthroplasty but methodological problems prevent exact interpretation of previous studies. METHODS: In a randomized, double-blind placebo-controlled trial in 12 patients undergoing bilateral total hip arthroplasty (THA) in a fast-track setting, saline or high-volume (170 mL) ropivacaine (0.2%) with epinephrine (1:100,000) was administered to the wound intraoperatively along with supplementary postoperative injections via an intraarticular epidural catheter. Oral analgesia was instituted preoperatively with a multimodal regimen (gabapentin, celecoxib, and acetaminophen). Pain was assessed repeatedly for 48 hours postoperatively, at rest and with 45° hip flexion. RESULTS: Pain scores were low and similar between ropivacaine and saline administration. Median hospital stay was 4 (range 2–7) days. INTERPRETATION: Intraoperative high-volume infiltration with 0.2% ropivacaine with repeated intraarticular injections postoperatively may not give a clinically relevant analgesic effect in THA when combined with a multimodal oral analgesic regimen with gabapentin, celecoxib, and acetaminophen.